Article citationsMore>>

P. A. Albertsson, R. Kohnke, S. C. Emek, J. Mei, J. F. Rehfeld, H. E. Akerlund and C. Erlanson-Albertsson, “Chloroplast Membranes Retard Fat Digestion and Induce Satiety: Effect of Biological Membranes on Pancreatic Lipase-Colipase,” Biochemical Journal, Vol. 401, No. 3, 2007, pp. 727-733. doi:10.1042/BJ20061463

has been cited by the following article:

• TITLE: Diabetics Have the Same Risk and Benefits Regarding Postoperative Amiodarone Prophylaxis for Atrial Fibrillation When Undergoing Surgery for Lung Cancer

  AUTHORS: Lars P. Riber, Thomas D. Christensen, Hans K. Pilegaard

  KEYWORDS: Lung Surgery; Atrial Fibrillation; Diabetics

  JOURNAL NAME: Open Journal of Thoracic Surgery, Vol.3 No.2, June 5, 2013

  ABSTRACT: Background: To evaluate if the risk for developing atrial fibrillation after lung surgery is higher for diabetics than non-diabetic patients and whether diabetic status prolongs the length of in-hospital stay. Objective: To compare the outcome of amiodarone prophylaxis in diabetics and non-diabetics. Design: Subgroup analysis within a randomized, controlled, double-blinded trial. Results: Development of atrial fibrillation was equally frequent among diabetics (18.2%) and non-diabetics (20.5%) (p = 1.00). Atrial fibrillation occurred in 7.1% of prophylactic diabetics and in 9.3% of prophylactic non-diabetics, while 37.5% non-prophylactic diabetics and 31.3% non-prophylactic non-diabetics experienced atrial fibrillation (p = 0.31). Prophylactic amiodarone was equally effective in diabetics as in non-diabetics with a relative risk of 3.5 (1.8 - 67.0) and the number need to treat of 4.4 (3.3 - 8.3) (p = 0.31). The length of in-hospital stay for diabetics was equal to non-diabetics with an average stay of 7.1 versus 8 days at Aarhus University Hospital (p = 0.61) with similar stays at intermediary and intensive care unit as well as total in-hospital stay of 8.9 versus 10 days (p = 0.60). Conclusions: Diabetics have the same risk of atrial fibrillation and the same benefits from prophylactic amiodarone as non-diabetics after surgery for lung cancer. Furthermore, diabetics have the same length of stay as non-diabetics. No severe adverse effects were found in either group.